Login to Your Account

Pharma: Other News To Note

Tuesday, April 17, 2012
• Conformetrix Ltd., of Manchester, UK, and AstraZeneca plc, of London, signed a research collaboration agreement allowing AstraZeneca to apply Conformetrix's NMR-based technology across its preclinical therapeutic pipeline to enhance lead discovery and hit identification.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription